TITLE

Whatever Your Problem

AUTHOR(S)
Burrus, Daniel; Mann, John David
PUB. DATE
February 2011
SOURCE
Leadership Excellence Essentials;Feb2011, Vol. 28 Issue 2, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses ways to address an unmanageable problem by skipping it to identify and thus solve the real problem, noting that the process is akin to peeling an onion. It cites the case of Eli Lilly which addressed the problem of an expiring drug patent in 2001 by initiating an innovative process to solve the real problem which in turn led to the development of new drugs. It emphasizes the need to approach a problem by focusing on the real issue and skipping one layer at a time until the center is exposed.
ACCESSION #
57961695

 

Related Articles

  • Post Prozac, Lilly stronger.  // Indianapolis Business Journal;12/31/2001, Vol. 22 Issue 43, p3 

    Focuses on the effect of the expiration of Prozac patent on the sales of Eli Lilly and Co. in the United States. Reduction of profit forecast; Strategies adopted by the company; List of drugs launched by the company.

  • Eli Lilly Needs New Drugs To Counter Prozac Ruling. Jarvis, Lisa // Chemical Market Reporter;09/25/2000, Vol. 258 Issue 13, p5 

    States that Eli Lilly & Co. needs to rely on its new drugs as the United States federal court of appeals ruled against the company over double patenting of Prozac. Implication of the loss of Prozac's patent on the company's stock value; Eli Lilly products that have blockbuster potential.

  • Lilly gets ready for life after Prozac.  // Indianapolis Business Journal;7/2/2001, Vol. 22 Issue 16, p3A 

    Reports that pharmaceutical company Eli Lilly and Co. wants to take full advantage of drugs it launched in the last half of the 1990s to replace an anticipated drop in Prozac revenue. Plan to continue developing a pipeline of products; Maintenance of leadership in developing drugs to treat...

  • SAD BUT TRUE.  // TCE: The Chemical Engineer;Apr2008, Issue 802, p80 

    The article focuses on the intention of drug manufacturer Eli Lilly to make future Prozac consists entirely of sugar. This decision would please investors because it was entirely in line with the very latest medical research. But commentators are doubtful that the tactic would pass Food and Drug...

  • Chapter 4: Prozac Revolution.  // History of Depression: The Mind-Body Connection;2007, p76 

    Chapter 4 of the book "The History of Depression: The Mind-Body Connection" is presented. It focuses on the development of an antidepressant drug called Prozac. Several developments on serotonin by researchers were conducted which revealed that altering levels of serotonin can produce behavioral...

  • Battles over pill patents begin. Lovern, Blair // Employee Benefit News;09/15/2000, Vol. 14 Issue 11, p1 

    Explores the impact of a United States (U.S.) court decision to remove the patent protection from Eli Lilly's antidepressant drug Prozac on prescription drugs in the U.S. Effect on Prozac's therapeutic category; Spending and use of psychiatric drugs in the U.S.; Sales of Prozac in 1999; Patents...

  • Adolor Pays $2M Up Front for Lilly Phase I Bowel Drug. Hollingsworth, Catherine // BioWorld Today;9/23/2009, Vol. 20 Issue 183, p1 

    The article reports that Adolor Corp. bought rights to Eli Lilly and Co.'s early stage product for opioid-induced bowel dysfunction (OBD) for 2 million U.S. dollars plus 70 million U.S. dollars. Such product and Adolor Corp.'s own pipeline bowel drug, ADL-7445, will be developed at the same time...

  • Born-Again Prozac: Not Worth the Extra Cost. Napoli, Maryann // HealthFacts;Jul2001, Vol. 26 Issue 7, p1 

    Announces the move of Eli Lilly company to release a repackaged version and a new dosage form of its antidepressant drug Prozac in the United States.

  • Lilly will boost Prozac spending.  // Indianapolis Business Journal;02/02/98, Vol. 18 Issue 47, p5 

    Discloses Eli Lilly & Co.'s plans to spend $40 million to $60 million into direct consumer advertising for its antidepressant, Prozac. Nine percent sales increase in fiscal 1997; Revenue losses experienced in fiscal 1997; Operating income increase for fiscal year 1997.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics